Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7251 results

Sort By:

A Study of EP0031 in Patients With Advanced RET-altered Malignancies

Study ID: NCT05443126
Start Date: 2022-09-30
End Date: 2027-06
Study Type

Interventional

Study Phase

Phase2

No. of Participants

265

Intervention / Treatment

EP0031

Sponsor

Ellipses Pharma

Source: clinicaltrials.gov

Share:
Add to list

EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers

Study ID: NCT05176665
Start Date: 2021-10-21
End Date: 2025-12-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

152

Intervention / Treatment

EMB-01

Sponsor

Shanghai -Tipmab Biotherputics., Ltd.

Source: clinicaltrials.gov

Share:
Add to list

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Study ID: NCT06743126
Start Date: 2025-01-14
End Date: 2031-10
Study Type

Interventional

Study Phase

Phase3

No. of Participants

360

Intervention / Treatment

Yum 03

nivolumab plus relatlimab

lifileucel

Nivolumab

pembrolizumab

ipilimumab

Dacarbazine

temozolomide

paclitaxel

paclitaxel plus carboplatin

Albumin-Bound Paclitaxel

Sponsor

Immatics US, Inc.

Source: clinicaltrials.gov

Share:
Add to list

Integrative Approaches for Cancer Survivorship (IACS3)

Study ID: NCT06633926
Start Date: 2025-03-31
End Date: 2027-06-30
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

104

Intervention / Treatment

Nutrition Education

Lifestyle Counseling

Yoga

Marma therapy

Educational Intervention

Quality of Life Questionnaire Administration

Sponsor

University of California, San Francisco

Source: clinicaltrials.gov

Share:
Add to list

ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma

Study ID: NCT04634357
Start Date: 2022-07-19
End Date: 2028-01-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

15

Intervention / Treatment

ET140203 T Cells

Sponsor

Eureka Therapeutics Inc.

Source: clinicaltrials.gov

Share:
Add to list

PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer

Study ID: NCT06083857
Start Date: 2024-06-18
End Date: 2027-12-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

60

Intervention / Treatment

Amivantamab

Tepotinib

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Preserving Physical Function in Older Adults With Cancer: Impact of an Optimizing Nutrition Intervention Applied Before and After Surgery

Study ID: NCT05912257
Start Date: 2024-05-01
End Date: 2027-06-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

188

Intervention / Treatment

Structured perioperative nutrition and exercise

Nutrition and Exercise Counseling

Sponsor

VA Office of Research and Development

Source: clinicaltrials.gov

Share:
Add to list

[18F] F-GLN by PET/CT in Breast Cancer

Study ID: NCT03863457
Start Date: 2019-04-05
End Date: 2026-12
Study Type

Interventional

Study Phase

Phase1

No. of Participants

40

Intervention / Treatment

Fluoroglutamine [18F]F-GLN

Sponsor

Abramson Cancer Center at Penn Medicine

Source: clinicaltrials.gov

Share:
Add to list

BP1001-A in Patients With Advanced or Recurrent Solid Tumors

Study ID: NCT04196257
Start Date: 2022-08-19
End Date: 2027-10
Study Type

Interventional

Study Phase

Phase1

No. of Participants

50

Intervention / Treatment

BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)

BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel

Sponsor

Bio-Path Holdings, Inc.

Source: clinicaltrials.gov

Share:
Add to list

Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

Study ID: NCT05283226
Start Date: 2022-09-30
End Date: 2026-01-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

30

Intervention / Treatment

NRC-2694-A

Paclitaxel

Sponsor

NATCO Pharma Ltd.

Source: clinicaltrials.gov

Share:
Add to list